Find us at our booth this weekend at the 37th National Cystic Fibrosis Education Conference hosted by the Cystic Fibrosis Research Institute. Hope to see you there!
4D Molecular Therapeutics
Biotechnology Research
Emeryville, California 13,307 followers
Powering the Future of Genetic Medicines
About us
4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Executive Relentlessly Join us in creating the future of genetic medicine.
- Website
-
http://www.4dmoleculartherapeutics.com/
External link for 4D Molecular Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Emeryville, California
- Type
- Public Company
- Founded
- 2013
- Specialties
- Gene Therapy, Adeno-Associated Virus, Biotechnology, Rare Diseases, Clinical, Lab, Clinical Trials, and Science
Locations
-
Primary
5858 Horton St
455
Emeryville, California 94608, US
Employees at 4D Molecular Therapeutics
-
Denis Bronnikov
Scientist | Dealmaker | Enabling Genetic Medicines Reach Millions of Patients
-
Frazana S.
Talent Acquisition Leader | Recruiting Strategy | Building High-Performing Teams - Focused on Rapid Growth and Scalability
-
Eden Bautista
Executive Assistant @ 4D Molecular Therapeutics
-
Katy Barglow
SVP Technical Operations at 4D Molecular Therapeutics
Updates
-
4DMT is on a mission to unlock the full potential of 4D-150 as a pipeline-in-a-product with multiple large market ophthalmic market opportunities, including the treatment of #wetAMD. We look forward to initiating our first Phase 3 #ClinicalTrial in wet AMD in Q1 2025. Our Co-founder & CEO, David Kirn, MD, discussed the recent interim 24-week landmark Phase 2 data presented at #ASRS2024 with Healio | Ocular Surgery News.
One intravitreal injection of 4D-150 helped reduce the mean annualized anti-VEGF injection rate in patients with #wetAMD. Healio spoke with David Kirn, MD, of 4D Molecular Therapeutics about the news 👇 #OcularSurgeryNews #Retina #ASRS2024 ASRS – American Society of Retina Specialists https://lnkd.in/eiyzYGha
-
-
#ICYMI Last week we reported positive initial interim 24-week landmark data from our PRISM Phase 2 Clinical Trial in a broad #wetAMD patient subset. Hear from our Co-founder and CEO, David Kirn, MD, share key findings from the data and provide a program update. Listen to the full webcast here: https://lnkd.in/g3Vw2Ecz
-
We are pleased to announce positive initial interim 24-week landmark data from the Population Extension cohort of our PRISM Phase 2 Clinical Trial, evaluating intravitreal 4D-150 in a broad #wetAMD patient population. Raj K. Maturi, M.D. (raj maturi), presented the data earlier this morning at the ASRS – American Society of Retina Specialists 42nd Annual Scientific Meeting in Stockholm, Sweden. 4D-150 continues to be safe and well tolerated across all patients dosed to date in both PRISM and SPECTRA clinical trials. We look forward to finalizing our Phase 3 PRISM #ClinicalTrial design later this year and progressing toward trial initiation in Q1 2025. Register for our webcast at 6:30 am ET, where our 4DMT management team and lead Principal Investigator, Arshad M. Khanani, will discuss the positive data and the #retinal program’s next steps. https://lnkd.in/eapkugkk #ASRS2024 #ophthalmology
-
Following #ECFS2024, Jennifer Taylor-Cousar, M.D., #ClinicalTrial Principal Investigator, discussed the progress of the AEROW trial investigating 4DMT’s aerosolized 4D-710 gene therapy candidate for CFTR modulator-ineligible/-intolerant #cysticfibrosis (CF) lung disease. Listen to Dr. Taylor-Cousar as she dives into the data she presented at the conference and shares an update on the trial’s next steps with CGTLive. https://lnkd.in/ePRDPtsc
-
#CEOSpotlight: The July issue of Drug Discovery News took a look at the history of oncolytic viral therapies and highlighted 4DMT Co-founder and CEO, David Kirn, MD's, contributions to this pioneering field. David’s groundbreaking work in #geneticengineering has opened new avenues in the field of virology. His innovative approach and dedication have significantly advanced the development of engineered viruses, showcasing the potential of genetic engineering in therapeutic applications. Learn more about his remarkable journey and contributions to the field here: https://lnkd.in/ghi8Y6cP
-
-
Our Co-founder and CEO, David Kirn, MD, recently shared updates on 4DMT’s #retinal programs – including 4D-150 for #wetAMD and #DME, and 4D-175 for the treatment of #geographicatrophy – with Healio | Ocular Surgery News at CTS Retina. David also provided insight into the next steps in developing these programs, with the initiation of the wet AMD Phase 3 #clinicaltrial expected in Q1 2025 and reporting Phase 2 clinical trial data in #DME later this year. #ophthalmology
4D-150 demonstrated positive safety, retinal anatomy and durability results, as well as a reduction in the need for annualized anti-VEGF injections in patients with wet #AMD, in the PRISM phase 2 clinical trial. The company has also filed an investigational new drug application for 4D-175 for the treatment of #geographicatrophy. David Kirn, MD, of 4D Molecular Therapeutics spoke with Healio at CTS Retina 🔗 #OcularSurgeryNews #ophthalmology #CTSRetina #Retina https://lnkd.in/ehKwBDpq
-
-
Age-related macular degeneration (AMD) affects the area where our sharpest vision occurs – our central vision. If you have AMD, you might find it challenging to see people’s faces, read, drive or take part in other daily activities. Compared to dry AMD #wetAMD generally causes more rapid and serious vision loss and may progress to blindness without treatment. These challenges may interfere with your social life and your sense of independence, making it harder to manage your daily needs and responsibilities. At 4DMT, we’re on a mission to unlock the full potential of genetic medicines for large market diseases like wet AMD. Learn more about our customized vector platform and wet AMD genetic medicine candidate: https://ow.ly/xn3i50Sv6XK
-
Last week, we gathered for our first in-person All Hands of the year. It was a fantastic opportunity to celebrate our achievements from 2024 thus far, including our 9th IND/CTA clearance since our first in 2018. Highlights included updates from our executive team on our #clinical progress, a look ahead to H2 milestones, a lively Q&A session and welcoming 26 new team members to #4DMT! Thank you to everyone who made this event a success. Together, we continue to break boundaries and work as a team to prepare and execute relentlessly to reach our goals. Follow along as we continue this exciting journey.
-
#WetAMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the retina. As a result, CNV causes swelling and edema of the retina, bleeding and scarring, visual distortion and reduced visual acuity. Without treatment, this process can cause irreversible damage to central vision and potentially lead to blindness. Our lead clinical candidate, 4D-150, has the potential to significantly reduce treatment burden and control disease activity, revolutionizing the treatment approach for patients with wet AMD. Learn more about 4D-150: https://lnkd.in/gsyvT_a2